Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown GDC-0980 malignant pleural mesothelioma not applicable detail...
PIK3CA R88Q GDC-0980 malignant pleural mesothelioma sensitive detail...
Unknown unknown Trabectedin malignant pleural mesothelioma not applicable detail...
Unknown unknown Cisplatin + Trabectedin malignant pleural mesothelioma not applicable detail...
Unknown unknown Obatoclax + Trabectedin malignant pleural mesothelioma not applicable detail...
Unknown unknown Trabectedin + Venetoclax malignant pleural mesothelioma not applicable detail...
Unknown unknown SEPREHVIR malignant pleural mesothelioma not applicable detail...
Unknown unknown AZD4547 malignant pleural mesothelioma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00996385 Phase II Bortezomib + Oxaliplatin Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status
NCT01064648 Phase Ib/II Cediranib + Cisplatin + Pemetrexed Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Active, not recruiting
NCT01265433 Phase II Sargramostim WT1 vaccine Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Completed
NCT01769547 Phase II Dovitinib A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy Terminated
NCT01868022 Phase I Docetaxel Cisplatin + Pemetrexed GSK3052230 Carboplatin + Paclitaxel Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling Completed
NCT01870609 Phase II Defactinib Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma Terminated
NCT01890980 Phase II WT1 vaccine Sargramostim Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134 Active, not recruiting
NCT01907100 Phase III Cisplatin + Pemetrexed Nintedanib Nintedanib (BIBF 1120) in Mesothelioma Terminated
NCT02004028 Phase II Defactinib Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma. Terminated
NCT02399371 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Malignant Mesothelioma Active, not recruiting
NCT02414269 Phase I Cyclophosphamide + iCasp9M28z T cells iCasp9M28z T cells Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Recruiting
NCT02568449 Phase II Nintedanib Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent Active, not recruiting
NCT02592551 Phase II Durvalumab + Tremelimumab Durvalumab MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma Active, not recruiting
NCT02639091 Phase I Anetumab ravtansine + Cisplatin + Pemetrexed Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Completed
NCT02707666 Phase I Pembrolizumab Cisplatin + Pemetrexed A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma Recruiting
NCT02709512 Phase II Cisplatin + Pemetrexed ADI-PEG 20 + Cisplatin + Pemetrexed Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC) Recruiting
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Recruiting
NCT02784171 Phase II Cisplatin + Pemetrexed Pembrolizumab Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Recruiting
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed
NCT02899195 Phase II Cisplatin + Durvalumab + Pemetrexed Durvalumab Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505) Active, not recruiting
NCT02899299 Phase III Carboplatin + Cisplatin + Pemetrexed Ipilimumab + Nivolumab Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743) Active, not recruiting
NCT02959463 Phase I Pembrolizumab Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma Recruiting
NCT03023319 Phase I Bosutinib + Pemetrexed Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Recruiting
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting
NCT03075527 Phase II Durvalumab + Tremelimumab A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma Suspended
NCT03126630 Phase Ib/II Pembrolizumab Anetumab ravtansine + Pembrolizumab Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma Recruiting
NCT03175172 Phase II CRS-207 + Pembrolizumab Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM Terminated
NCT03228537 Phase I Atezolizumab + Cisplatin + Pemetrexed Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma Active, not recruiting
NCT03319537 Phase Ib/II MLN4924 Cisplatin + MLN4924 + Pemetrexed Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma Recruiting
NCT03399552 Phase Ib/II Avelumab Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma Recruiting
NCT03644550 Phase II LMB-100 + Pembrolizumab Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma Recruiting
NCT03710876 Phase III Celecoxib + Gemcitabine Celecoxib + Gemcitabine + rAd-IFN Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE) Recruiting
NCT03715933 Phase I INBRX-109 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Recruiting
NCT03717415 Phase Ib/II Carboplatin + Rebastinib A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors Recruiting
NCT03760575 Phase I Cisplatin + Pembrolizumab + Pemetrexed Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) Not yet recruiting
NCT03918252 Phase II Ipilimumab + Nivolumab Nivolumab Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Recruiting
NCT03920839 Phase I Carboplatin + INCMGA00012 + Paclitaxel Cisplatin + Gemcitabine + INCMGA00012 Cisplatin + INCMGA00012 + Pemetrexed Carboplatin + INCMGA00012 + Pemetrexed INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) Withdrawn
NCT04013334 Phase II MTG201 + Nivolumab MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma Recruiting
NCT04040231 Phase I Galinpepimut-S + Nivolumab + Sargramostim Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma Recruiting
NCT04042480 Phase I SGN-CD228A A Study of SGN-CD228A in Advanced Solid Tumors Recruiting
NCT04162015 Phase I Cisplatin + Nivolumab + Pemetrexed Carboplatin + Nivolumab + Pemetrexed A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma Recruiting
NCT04201145 Phase I Pembrolizumab Defactinib + Pembrolizumab Pembrolizumab + Defactinib In Pleural Mesothelioma Not yet recruiting
NCT04345705 Phase I Poly ICLC Direct Injection of Poly-ICLC (Hiltonol) Vaccine In Malignant Pleural Mesothelioma Not yet recruiting